Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab via DoseConnect + Nivolumab in Metastatic Melanoma
NCT04967196Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Sep 2021
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ipilimumab in melanoma (2 cohorts), sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose at 21 days, Incidence of Adverse Events at 21 days and 2 more. Started Sep 2021; status: terminated.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04967196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04967196.